Category: Solutions

How much proof do you want? Hundreds of studies conclude – treat Covid-19 early with hydroxychloroquine!

HCQ is effective for COVID-19. The probability that an ineffective treatment generated results as positive as the 235 studies to date is estimated to be 1 in 6 quadrillion (p = 0.00000000000000018).
Early treatment is most successful, with 100% of 29 studies reporting a positive effect (13 statistically significant in isolation) and an estimated reduction of 65% in the effect measured (death, hospitalization, etc.) using a random effects meta-analysis, RR 0.35 [0.25-0.50].
92% of Randomized Controlled Trials (RCTs) for early, PrEP, or PEP treatment report positive effects, the probability of this happening for an ineffective treatment is 0.0017.

Read More »

NIH to Launch Massive ACTIV-6 Phase 3 Clinical Study Investigating Repurposed Drugs & Ivermectin May be on the List

NIH will provide an initial investment of $155 million in funding for the trial. TrialSite picked up inside rumblings that ivermectin will be one of the economical drugs under investigation. While this study is late in the pandemic, nonetheless TrialSite celebrates Collins and team’s movement in this most important of areas. We don’t currently have approved medication to be self-administered by people suffering mild disease at home & reduce the chance of needing hospitalization.

Read More »

Doctor’s Advice on Early Treatment for COVID-19

Every viral illness starts that way. The more it’s allowed to progress, the more it takes over the cells and replicates itself. That’s why this virus absolutely had to be treated early to prevent those damages. Primarily what has killed people with COVID is a delay to treatment, and allowing the exaggerating inflammatory response and blood clotting response to take hold in the body.

Read More »

American Hero: Ralph C. Lorigo Fights for Client Rights Including Access to Ivermectin for COVID-19 Patients At Risk

Lorigo shared with TrialSite that once doctors learn of all of the studies around the world, and start doing their own homework, they become more open-minded, factoring in the risk-reward analysis. Especially if elderly high risk patients present advanced COVID-19, Lorigo has personally seen the drug potentially contribute to saving the lives of clients. Interestingly, the attorney reports that it would appear that hospital administrations are the most recalcitrant to the idea, even if the patients and the ICU doctor are in support.

Read More »

The Chloroquine Wars Part XIV – How to Rig Research: Surgisphere Part I

It was in these very moments in late May when public health officials lost all credibility—a credibility that cannot be restored without major changes taking place. Despite most evidence pointing to a likelihood of HCQ efficacy, they made their call on the back of data supposedly tucked away in a database that nobody had verified, declared it definitive, then swiftly pushed for policy changes around the world.

Read More »

Hyperglycemia, hydroxychloroquine and the COVID‐19 pandemic

Hydroxychloroquine also can act as an oral hypoglycemic agent, as patients with diabetes taking hydroxychloroquine for rheumatologic diseases had a significant reduction in hemoglobin A1c when compared to methotrexate,40 and thus can serve to reduce hyperglycemia, a possible COVID‐19 risk factor for disease severity.

Read More »

Another New York State Supreme Court Justice Ivermectin Order Helping 81-Year-Old Farmer

Ivermectin, a medicine for parasites, has been around for four decades. While not authorized for use against COVID-19, dozens of studies show materially positive results. At well-established human dosage levels, the drug is safe: hundreds of millions of people are treated with it every year mostly in the tropics for various parasite-borne diseases, such as River Blindness in Nigeria.

Read More »

The Chloroquine Wars Part XIII -A Clockwork Orange Man

Immediately following HCQ’s Trump moment, the media went on an all-out blitz to associate the topic of HCQ with a sense of fear. Fear of Trump, fear of death, fear of incompetence, fear of opposing scientific authorities, fear of using medicine needed by somebody else, and fear of the unknown. And the campaign of fear didn’t stop there.

Read More »

Clinical outcomes of patients with mild COVID-19 following treatment with hydroxychloroquine in an outpatient setting

Our investigation of a large national cohort appears to support early administration (within the first 3 to 7 days of COVID-19 diagnosis) of HCQ in mild COVID-19 disease in an outpatient setting for reducing hospitalizations and deaths without any serious adverse HCQ-related effects.
If this finding is confirmed in future clinical trials, HCQ as a cheap and available drug may still play a role in a specific population with respect to reducing COVID-19 burden, particularly in resource-poor countries.

Read More »

Front Line COVID-19 Critical Care Alliance Statement – Weak Guidance on Ivermectin from the World Health Organization (WHO)

“I am deeply troubled that the WHO made this hasty decision on guidance before reviewing all available data,” said Pierre Kory, MD, MPH, president and chief medical officer of the FLCCC.
“Their recommendation ignores the evidence, creates more controversy, and will only lead to continuing suffering and death from COVID-19. There are now over 24 randomized trials results
that have been reported to the Unitaid/WHO team yet todays guidance was inexcusably based on a faulty analysis of just 16 of the available trials. Further, these erroneous findings directly conflict
with numerous other peer-reviewed expert analyses that have found the data overwhelmingly demonstrates that ivermectin saves lives from COVID-19. There is no reason not to recommend it
for everyone as a safe drug for prevention and treatment.”

Read More »

A RANDOMIZED TRIAL – INTENSIVE TREATMENT BASED IN IVERMECTIN AND IOTA-CARRAGEENAN AS PRE-EXPOSURE PROPHYLAXIS FOR COVID- 19 IN HEALTHCARE AGENTS

The purpose of this study was to assess the effect of oral Ivermectin treatment, which has been associated with iota-carrageenan in repeated doses through the nasal and oral topical route, on the appearance and eventual progression of COVID-19 disease in a healthy population that are exposed to it and have a higher risk of contagion of SARS-COV-2 for being health personnel from

Read More »

Hydroxychloroquine or Ivermectin? The Netherlands’ Nonsense Beats Australia’s !!!

Did the Netherlands work out that early outpatient treatment using hydroxychloroquine, ivermectin & other drugs, hospitalisations can reduce by 80% or more?
It would take just a few weeks to bring down new hospitalizations for COVID-19 to around 40 per day in the country, if general practitioners were authorized to treat the disease early, using a range of early treatment medications, including those now exposing doctors to penalties of up to 150,000 euros!

Read More »

Association of Italian Doctors successfully treats COVID patients with vitamin D and hydroxychloroquine

From an ingenious intuition of the founder, Mauro Rango, an Italian living in the Mauritius Islands. There, the Coronavirus was quickly eradicated in the beginning, with drugs that we have known for decades, such as Azithromycin, Hydroxychloroquine or Cortisone, while in Italy people died like flies. How was it possible that in Africa, where health care is not as advanced as in Italy, such marvellous results were achieved, while in Italy the spread of the disease could not be contained?

Read More »